âIncredibly Encouragingâ Drug Trial Shrinks Tumors in Head and Neck Cancer Patients Within Six Weeks.
The triple-action injection-based therapy targets metastatic head and
neck squamous cell carcinoma (HNSCC), a hard-to-treat form of head and
neck cancer, considered the 6th-most common form of the disease.
